Prelude Therapeutics (PRLD) 2025 Conference Transcript

Summary of Prelude Therapeutics Conference Call Company Overview - Prelude Therapeutics is a precision oncology company focused on discovering and developing novel small molecules and degrader antibody conjugates for aggressive cancers that lack effective therapies [5][6] Key Updates and Core Points - Lead Clinical Program: The lead program targets the chromatin remodeling complex SMARCA2, with the first clinical candidate being a selective degrader molecule named 3,789, currently in clinical trials [5][6] - Clinical Data: Recent data presented showed a 23% response rate in patients with upper GI and lung tumors having SMARCA4 mutations at doses greater than 283 mg [11] - Dose Selection: The recommended phase 2 dose (RP2D) for the IV molecule has been set at 500 mg based on safety and efficacy data [11][13] - Oral Molecule Development: An oral molecule, 7,732, began clinical trials late last year, with rapid progress noted in patient enrollment and dose escalation [7][22] - Research and Development: Prelude is also advancing a new program called Cat6 Degrader, which is a selective degrader targeting Cat6a, with potential advantages over existing inhibitors [8][45] Upcoming Catalysts - Data Updates: The company plans to provide updates on both the IV and oral programs later this year, with a focus on the totality of phase one data and ongoing patient enrollment [16][23] - IND Submission: For the Cat6a program, the company aims to select a development candidate soon and hopes to submit an IND in early 2026 [48] Financial Position - As of the end of the last quarter, Prelude had $103 million in cash, which is expected to support operations into the second quarter of the following year [58] Competitive Landscape - Prelude acknowledges competition in the SMARCA space but emphasizes the unique aspects of their degrader approach, which may offer better safety profiles and efficacy compared to existing therapies [37][39] Additional Insights - Partnerships: Prelude is collaborating with Absella on developing dual degraders conjugated to antibodies, which have shown promising preclinical results [53][54] - Patient Selection: The company has established a biomarker for patient selection, enhancing the potential for successful clinical outcomes [21][39] Conclusion - Prelude Therapeutics is positioned well within the oncology space, with a strong pipeline of innovative therapies and a solid financial foundation to support its clinical and preclinical endeavors. The focus on selective degraders and the rapid advancement of both IV and oral programs highlight the company's commitment to addressing unmet medical needs in aggressive cancers [5][58]